Skip to main content
. 2014 Sep 12;21(4):385–391. doi: 10.1111/cns.12326

Figure 3.

Figure 3

SS‐31 treatment attenuates CD36 and inflammatory response and ischemic/reperfusion injury. (A–C) Brain CD36 (A), MCP‐1 (B), and CCR2 (C) mRNA levels in mice treated with vehicle or SS‐31 24 h after tMCAO. n = 5–6/group, *P < 0.05, **P < 0.01, and ***P < 0.001 versus contralateral, # P < 0.05 and ### P < 0.001 versus veh, two‐way ANOVA, (D and E) stroke outcome measurement 3 days after tMCAO. (D and E) Infarct volume (D) and % swelling (E), n = 12–20/group, *P < 0.05 and **P < 0.01 versus veh, Student's t‐test.